Medical paternalism and expensive unsubsidised drugs. by Jefford, M, Savulescu, J, Thomson, J, Schofield, P, Mileshkin, L, Agalianos, E, Zalcberg, J

Do oncologists discuss expensive anti-cancer drugs with their patients? by Thomson, J, Schofield, P, Mileshkin, L, Agalianos, E, Savulescu, J, Zalcberg, J, Jefford, M

To tell or not to tell: the community wants to know about expensive anticancer drugs as a potential treatment option. by Mileshkin, L, Schofield, P, Jefford, M, Agalianos, E, Levine, M, Herschtal, A, Savulescu, J, Thomson, J, Zalcberg, JR

Phase IB dose-escalation and expansion study of AKT kinase inhibitor afuresertib with carboplatin and paclitaxel in recurrent platinum-resistant ovarian cancer by Blagden, S, Hamilton, A, Mileshkin, L, Wong, S, Michael, A, Hall, M, Goh, J, Lisyanskaya, A, Desilvio, M, Frangou, E, Stronach, E, Gopalakrishna, P, Meniawy, T, Gabra, H

Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibitio... by Eggink, F, Van Gool, I, Leary, A, Pollock, P, Crosbie, E, Mileshkin, L, Jordanova, E, Adam, J, Freeman-Mills, L, Church, D, Creutzberg, C, De Bruyn, M, Nijman, H, Bosse, T